U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
186.64-1.53 (-0.81%)
At close: 4:00PM EDT

186.60 -0.04 (-0.02%)
After hours: 6:50PM EDT

People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close188.17
Open188.32
Bid186.60 x 300
Ask188.19 x 100
Day's Range186.50 - 188.96
52 Week Range133.64 - 191.10
Volume2,082,214
Avg. Volume2,796,482
Market Cap136.19B
Beta1.79
PE Ratio (TTM)17.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.47%)
Ex-Dividend Date2017-08-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
    Zacks12 hours ago

    Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

    Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • American City Business Journals2 days ago

    Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA

    A "biosimilar" version of the cancer drug Avastin — Genentech Inc.'s best-selling oncology treatment — was approved Thursday by the Food and Drug Administration, potentially crimping the $6 billion franchise of the South San Francisco-based drug maker's Swiss parent. The drug, which Amgen Inc. (AMGN) and partner Allergan plc (AGN) will sell as Mvasi, also is known by the scientific name bevacizumab. The drug regulator's approval allows it to be used to treat metastatic colorectal cancer and types of lung, kidney, cervical and brain cancers.